Botulinum toxin A (Q-Med)

Based on the price range, Galderma will have a forecast market capitalisation of up to CHF 12.6bn. Image credit: Shutterstock/JHVEPhoto. Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares. An over-allotment of up to 6,109,158 existing shares at Galderma’s prescribed price range means the IPO could fetch as much as CHF 2.3bn. Galderma stated the offer period starts today, and is expected to end on 20 March. The final offer price will be published the day after. The company will officially begin trading on 22 March, as per a 13 March press release. Based on the price range, Galderma will have a forecast market capitalisation of up to CHF 12.6bn, as per the company. Galderma has said that the equity raise will be used to settle debt and develop its pipeline, according to the earlier press release this month. See Also: CTS Europe: The roadmap for generative AI in the pharma industry Biotechs heed political headwinds for drug pricing negotiations and partnerships The IPO is touted to be one of the largest listings in Europe in 2024 and the biggest since German car company Porsche AG went public in 2022. EQT , Galderma’s main shareholder, had been trying to take the skincare group public for some time but tough market conditions delayed the listing. Galderma raised $1bn through private placement in 2023 whilst the IPO was on hold. Galderma’s revenue grew by 8.5% in 2023 – bringing in sales of over $4bn . The company’s Cetaphil and Alastin brands, which include moisturisers, sunscreens for sensitive skin, and anti-ageing creams, are at the helm of its revenues. Galderma has also seen success in injectable aesthetics, gaining an US Food and Drug Administration (FDA) approval for its Botox competitor Azzalure in 2023. Galderma is working towards an approval for RelabotulinumtoxinA (QM-1114) for the treatment of frown lines and lateral canthal lines. The company suffered a setback with an FDA rejection for the botulinum formulation in September last year but said it has already identified the necessary changes for approval. Also in the company’s clinical pipeline is nemolizumab for the treatment of atopic dermatitis and prurigo nodularis. The drug is currently under review for marketing in the US and EU on the back of positive Phase III results . Galderma expects US approval in the first half of 2025 and has slated the drug to gain blockbuster status by 2027. GlobalData estimates the dermatology market size in the US was worth $26.5bn in 2023. GlobalData is the parent company of Pharmaceutical Technology .

Galderma will present two late-breaking presentations on clinical trials evaluating the long-term efficacy of the investigational monoclonal antibody nemolizumab in prurigo nodularis and its durability in atopic dermatitis1,2 Five oral posters and 16 e-posters will also be presented from across Galderma’s aesthetic, therapeutic dermatology and dermatological skincare portfolio, with data on acne, sensitive skin, aesthetic improvements and prurigo nodularis For the first time, Galderma will sponsor a symposium on the burden of itch in collaboration with the U.S. National Eczema Association, featuring renowned dermatology experts along with patient representatives ZUG, Switzerland--(BUSINESS WIRE)-- Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio. Galderma’s extensive presence – including two late-breaking presentations on its first-in-class, investigational monoclonal antibody nemolizumab, five oral poster presentations, 16 e-posters, a symposium, and several ‘Meet the Expert’ and interactive booth sessions – highlights its commitment to listening to consumers, patients and healthcare professionals in order to deliver cutting-edge science and innovation that addresses their varied needs. “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action. We particularly look forward to presenting the latest updates from clinical trials of nemolizumab, which was recently accepted for filing by regulatory authorities in the U.S. and EU in prurigo nodularis and atopic dermatitis.” BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA Data from across the full spectrum of dermatology to be presented New data on nemolizumab, a first-in-class, investigational monoclonal antibody specifically designed to provide safe and rapid relief from itch, will be shared at AAD in two late-breaking presentations: Results up to 52 weeks from an interim analysis of the OLYMPIA open-label extension study evaluating the long-term efficacy and safety of nemolizumab in patients with prurigo nodularis will be presented on Sunday, March 10, at 3:20 PM PST by Dr. Shawn Kwatra1 Results from an analysis of two pivotal phase III studies (ARCADIA 1 and ARCADIA 2) evaluating the efficacy and safety of maintenance treatment with nemolizumab at 48 weeks in patients with moderate to severe atopic dermatitis will be presented on Sunday, March 10, at 2:50 PM PST by Dr. Jonathan Silverberg2 Additionally, five oral posters will be presented on Friday, March 08, at the Upper Level, Sails Pavilion, Poster Center 1, including: Results from the phase III READY-3 study evaluating the efficacy and safety of RelabotulinumtoxinA, our investigational novel, ready-to-use liquid neuromodulator, when used for combination treatment of frown lines (glabellar lines) and crow’s feet (lateral canthal lines) at 9:50 to 9:55 AM PST, presented by Dr. Joel Schlessinger3 Results from the phase IV LEAP and START studies, showing that trifarotene improves acne and related sequelae at 9:05 to 9:10 AM PST, and that it is efficacious and suitable for a broad range of patient types at 8:35 to 8:40 AM PST, both presented by Dr. Andrew Alexis4,5 Survey results on sensitive skin, including on dermatologists’ perspectives and educational exposures at 3:50 to 3:55 PM PST, presented by Dr. Sara Abdel Azim, and primary hyperhidrosis and sensitive skin syndrome at 10:10 to 10:15 AM PST, presented by Dr. Cleo Whiting6,7 Delving into patient and expert perspectives on itch Our sponsored symposium, Perspectives on itch: Sharing experiences and understanding the burden, conducted in collaboration with the National Eczema Association, will bring together leading experts and patient representatives, Dr. Shawn Kwatra, Dr. Jonathan Silverberg, Dr. Matt Zirwas, and from the U.S. National Eczema Association, Wendy Begolka, to explore how dermatology providers can better recognize and address itch, one of the most burdensome and debilitating symptoms associated with diseases such as atopic dermatitis and prurigo nodularis. The event is taking place on Saturday, March 9, in the Pacific Ballroom 21-26, Marriott Marquis San Diego Marina, from 7:00 to 9:00 PM PST. More details on Galderma’s scientific presentations at AAD can be found here. *All presenters are paid consultants or employees of Galderma. About Galderma Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: . References Kwatra, S, et al. Nemolizumab long-term efficacy and safety up to 52 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: an interim analysis. Late-breaking abstract presented at AAD 2024. Silverberg, J, et al. Maintenance of efficacy and safety with nemolizumab at Week 48: results from two global phase III pivotal studies (ARCADIA 1 and ARCADIA 2) in patients with moderate-to-severe atopic dermatitis​. Late-breaking abstract presented at AAD 2024. Schlessinger, S, et al. Efficacy and safety of a novel formulation liquid botulinum toxin, RelabotulinumtoxinA, when used for combination treatment of glabellar and lateral canthal lines. Oral poster presented at AAD 2024. Alexis, A, et al. Trifarotene shown to improve acne and related sequelae. Oral poster presented at AAD 2024. Alexis, A, et al. Phase IV studies show trifarotene is efficacious and suitable for broad range of patient types. Oral poster presented at AAD 2024. Azim, SA, et al. Sensitive skin: a survey of dermatology resident physicians’ perspectives and educational exposures. Oral poster presented at AAD 2024. Whiting, C, et al. Primary hyperhidrosis and sensitive skin syndrome: a national pilot survey. Oral poster presented at AAD 2024. View source version on businesswire.com: Contacts Christian Marcoux, M.Sc. Chief Communications Officer christian.marcoux@galderma.com +41 76 315 26 50 Sébastien Cros Corporate Communications Director sebastien.cros@galderma.com +41 79 529 59 85 Emil Ivanov Head of Strategy, Investor Relations, and ESG emil.ivanov@galderma.com +41 21 642 78 12 Jessica Cohen Investor Relations and Strategy Director jessica.cohen@galderma.com +41 21 642 76 43 Source: Galderma View this news release online at: